title: Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.
abstract: BACKGROUND
  Mirasol pathogen reduction technology (PRT) treatment inactivates bacteria, viruses, and parasites in plasma products and platelets (PLTs) suspended in plasma and PLT additive solutions (PAS). Few clinical studies exist documenting transfusions with PAS. This study objective was to evaluate the count increments of PRT-treated PAS-C and PAS-E buffy coat (BC) PLTs in routine use observational settings.
  
  
  METHODS
  PLT pools of five or six BCs were collected, processed, and suspended in PAS-C or PAS-E, respectively. Products were exposed to ultraviolet light in the presence of riboflavin and then transfused into 19 patients with hematologic diseases. Patients were monitored for PLT corrected count increment (CCI) at 1 and 24 hours and for any adverse events in the 72 hours after transfusion. Sterility monitoring was performed with a microbial detection system (BacT/ALERT, bioMérieux).
  
  
  RESULTS
  The PAS-E products had significantly higher PLT concentrations and counts than the PAS-C products. The mean CCIs of per-protocol (PP) units at 1 and 24 hours were 11,900 (n=27) and 5500 (n=30), respectively. Seventy-eight percent of PP transfusions classify as successful with CCIs at 1 hour of higher than 7500, and 63% higher than 4500 at 24 hours. One patient was excluded from all analyses as she was refractory to Mirasol-treated PLT transfusions and follow-up untreated transfusion products. No adverse events were observed and no contaminated products were detected by BacT/ALERT.
  
  
  CONCLUSIONS
  PRT-treated BC PLTs in PAS-C or PAS-E demonstrate PLT transfusion success rates in hematology patients with thrombocytopenia that are comparable to previous studies examining PLTs stored in plasma.
authors.affiliation: Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Drawz
authors.affiliation: Terumo BCT, Lakewood, Colorado.
authors.forename: Susanne
authors.initials: S
authors.lastname: Marschner
authors.affiliation: CHEMCYL.
authors.forename: Martha
authors.initials: M
authors.lastname: Yañez
authors.affiliation: Hospital Clínico Universitario De Valladolid, Valladolid, Spain.
authors.forename: Alfonso
authors.initials: A
authors.lastname: García de Coca
authors.affiliation: Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.
authors.forename: Hendrik B
authors.initials: HB
authors.lastname: Feys
authors.affiliation: AZ Delta, Roeselare, Belgium.
authors.forename: Dries
authors.initials: D
authors.lastname: Deeren
authors.affiliation: Blood Service of the Belgian Red Cross-Flanders, Mechelen, Belgium.
authors.forename: José
authors.initials: J
authors.lastname: Coene
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001793:Blood Preservation; D004203:Disinfection / Q000379:methods; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000097:blood / Q000628:therapy; D007552:Isotonic Solutions; D017319:Photosensitizing Agents / Q000494:pharmacology; D010976:Platelet Count; D017713:Platelet Transfusion; D012256:Riboflavin / Q000494:pharmacology; D013997:Time Factors
chemical_list: D007552:Isotonic Solutions; D017319:Photosensitizing Agents; D012256:Riboflavin